Entities

Serial entrepreneur and co-founder of Sunstone.

Former India general manager at Flyhomes, with prior Fidelity experience and an integrated MTech from IIT Delhi.

Chartered accountant with a decade of finance and accountancy experience.

Previously a venture partner at Octopus Ventures in Singapore.

Previous experience at Oberoi Hotels and Resorts and Flyhomes.

Law and economics graduate with more than 15 years in international law firms working on acquisitions, financing rounds and company law; joined the university investment function in 2017.

Pharmacist, entrepreneur and business angel with experience in healthcare, pharmaceuticals, medical technology and company boards.

Investment and strategy professional with previous experience at Bessemer Venture Partners, Ola Electric and Piaggio corporate venture capital.

Pharmacist and entrepreneur with pharmaceutical sales and marketing experience, including Pfizer; co-built Netdoktor and has worked in medical education.

Finance graduate with nearly ten years of investment banking experience before joining the University of Helsinki investment function in 2019.

Former Slush global expansion professional and founding team member of a Finnish deep technology fund.

Entrepreneur who founded Pine Labs, GlobalLogic and Sunstone, with early angel investments including Meesho, 1mg and Reify Health.

Finance executive with previous experience at Peak XV Partners and Premji Invest.

Founder of Purvi Capital and co-founder of Jump Trading’s high-frequency trading group.

Healthcare and education entrepreneur who leads Leo Capital’s investments outside India.

Chartered accountant.

Chartered accountant with previous experience at JPMorgan Chase.

Helsinki University Funds is the University of Helsinki’s separate asset-holding and investment entity, legally Helsingin Yliopiston Rahastot. Within the university group it holds companies, properties and financial investments and supports research and education. Its venture activity backs spinouts and startups connected to university research, intellectual property and students, alongside a broader endowment invested primarily in diversified listed securities. It offers early pre-seed support and follow-on financing with other investors, and helps founding teams with governance, legal agreements and fundraising. Its governance is shared with the university: the university board also serves as the Funds board, supported by investment and commercialisation committees.

Generali Welion S.c.a.r.l. is the Italian Generali group company providing integrated welfare and health services, including employer benefit platforms, prevention programmes, digital access to care, medical-provider networks and support for elderly or dependent people and caregivers. Its current legal disclosure identifies tax code01202150320 and VAT01333550323; the shared VAT is not used to merge Welion with Generali Italia or the global insurer. Its registered office is in Trieste and operating offices are in Milan. The company was publicly launched as Generali Welion in2017, building on group health and employee-benefit expertise. Its digital-health and startup collaborations include the Open Accelerator2018 programme, in which Generali Welion provided a specifically announced EUR10,000 investment award to Mobile GaitLab, the Parkinson gait-monitoring project of Portabiles HealthCare Technologies. This establishes direct neuroscience and wearable-technology investment relevance without representing the services company as an independent venture-fund manager. Francesco Bardelli is confirmed as CEO by current company communications; Gianluca Perin is identified as Welion chairman in the parent’s current management biography. Prior CEOs are retained only as historical affiliations. Health-premium volumes, assisted-person counts and parent assets under management are operating statistics, not capital raised by Welion or a fund close. Public sources reviewed disclose no separate Welion LP fund or verified external company financing; strategic startup collaborations are not automatically recorded as equity investments.

Patrick Johnson leads Dassault Systèmes’ corporate research and sciences, a responsibility held since2004, and joined its executive committee in2023. He joined as a software engineer in1996 and subsequently led its artificial-intelligence department, including knowledge-based engineering. His current research remit spans data science, biology, medicine, chemistry, physics and other sciences underlying AI-powered virtual twins. He is distinct from similarly named professionals outside this software company.

Philippe Laufer has led Dassault Systèmes’ global brands since2020 and customer-engagement teams since2021. He joined CATIA R&D in1985, worked on Boeing777 and automotive programs, led CATIA shape-design R&D from1996 and global R&D from2006, and became CATIA CEO in2012. He earned mechanical-engineering and production-automation qualifications from École Centrale de Nantes and ENSTA and holds a systems-engineering doctorate.

Florence Hu-Aubigny is Dassault Systèmes’ executive vice president for research and development, joining its executive committee in2020 to oversee development activities. She started at the company in1991, contributed to functional modeling,3DVIA and ENOVIA, and led development of the3DEXPERIENCE platform from2012. She studied at CESTI, subsequently renamed Supméca, and undertook postgraduate computer-aided-production-management studies.

Grégory Abate has been Dassault Systèmes’ general secretary and an executive-committee member since2024, after joining as deputy general secretary in2023. His responsibilities include governance, public affairs, internal audit and controls. Earlier he served in France’s presidential and prime-ministerial offices, the Ministry of Finance and the European Commission. He studied at École des Mines, Sciences Po and ÉNA, earned a Sorbonne business-law master’s and worked as a Paris-bar lawyer.

Victoire de Margerie leads Dassault Systèmes’ corporate marketing, communication and identity and has served on the executive committee since2018. Her responsibilities include brand reputation, its3DEXPERIENCE Lab startup accelerator and public experiential spaces. She previously led international communications at Airbus. Her own biography identifies board roles at La Fondation Dassault Systèmes and Entreprises & Médias; these do not establish personal venture investments.

Laurence Barthès is Dassault Systèmes’ executive vice president and chief people and information officer. She joined its R&D organization in1987 leading quality, processes and production engineering, became vice president for customer support and satisfaction in2002, then led information systems in2008 and took her combined people/information executive role in2009. Her remit combines workforce development and information systems.

Rouven Bergmann became Dassault Systèmes’ executive vice president and CFO inJanuary2022. He previously oversaw Medidata operations as its life-sciences chief operating officer, having joined Medidata as CFO in2015 and supported its2019 acquisition by Dassault Systèmes. Earlier he was CFO of SAP North America. He holds master’s degrees in mechanical engineering and business administration from the Technical University of Kaiserslautern and a doctorate in economics and finance from the University of Munich.

Elisa Prisner is executive vice president for strategy, industry, marketing and transformation. She joined Dassault Systèmes in2013 working on the Airbus account and A350 virtual-twin project, then led corporate transformation from2017. She joined the executive committee in2022, with expanded industry, marketing and sustainability responsibilities from2025. Earlier she consulted on aeronautical and systems engineering at Aeroconseil. Her education includes engineering at ECAM Rennes, an ENAC master’s and a jointly awarded aerospace-focused MBA.

Armin Wiesler is a member of Boehringer Ingelheim’s Board of Managing Directors responsible for Animal Health. He previously led regional businesses inSoutheastAsia,Korea,Australia andNewZealand and managed Thailand operations. Earlier experience includes marketing, corporate strategy and McKinsey. He earned economics degrees at the University of Freiburg.

Erik Swedberg has led Dassault Systèmes’ Americas organization as an executive-committee member since2020. He joined through the2006 MatrixOne acquisition, where he led business consultants, and later managed aerospace transformation projects and the global Boeing relationship. He became managing director for North America in2019. He studied aerospace engineering at the University of Minnesota.

Florence Verzelen leads Dassault Systèmes’ Europe, Middle East and Africa business and its Infrastructure & Cities sector. She joined the company and executive committee in2018, initially responsible for industry, marketing and education, and developed its sustainability function. Previously she held senior regional, operating and business-development roles at Engie. She is a graduate of École Polytechnique and Corps des Mines.

Frank Hübler is a member of Boehringer Ingelheim’s Board of Managing Directors responsible for Finance. His earlier work covered treasury, accounting, control and tax, UK/Ireland finance, regional financial management and internal audit. He studied business administration at the Catholic University of Eichstätt-Ingolstadt. Current board responsibility is distinguished from older corporate-finance timeline descriptions.

Harsha Deshmukh is a member of Boehringer Ingelheim’s Board of Managing Directors responsible for IT and Global Business Services. He joined the board effectiveFebruary1,2026 after technology leadership atInfineon, including chief information officer. His earlier work included enterprise IT, supply-chain management and industrial automation. He studied engineering inMumbai and management programmes atBabson andINSEAD.

Hubertus von Baumbach is chairman of Boehringer Ingelheim’s Shareholders’ Committee, effectiveJuly1,2025 and reaffirmed in the company’s September2026statement. He joinedBoehringer in2001, joineditsBoardofManagingDirectors in2009 and chairedthatboard from2016until2025. ShashankDeshpande succeededhim as executive-boardchair. The governance role is distinct from currentchiefexecutive or venturefundpartner.

Pascal Daloz is Dassault Systèmes’ chairman and CEO, with the combined appointment effectiveFebruary21,2026. He became CEO in2024 after serving as deputy CEO in2023 and chief operating officer2020–2023; he joined the board in2020. His leadership has emphasized multidisciplinary technology, acquisitions, life sciences and healthcare. His own biography also identifies chair responsibilities at Medidata, Outscale and Centric PLM. This corporate executive identity does not establish a personal Click investment.

Samson Khaou leads Dassault Systèmes’ Asia-Pacific business and joined its executive committee in2020. His responsibilities cover South Asia, China, South Korea, India and Japan. He joined the company’s R&D organization in1989 and later worked in CATIA/ENOVIA presales, product-lifecycle-management competency centers and major automotive projects. His role involves customer relationships and regional adoption of virtual-twin technology.

Paola Casarosa is a member of Boehringer Ingelheim’s Board of Managing Directors responsible for Innovation. Earlier responsibilities included CNS, retinal diseases, emerging therapeutic areas, prescription-pharma business development and respiratory licensing. She trained in molecular pharmacology at VUAmsterdam and pharmaceutical chemistry inTurin.

Dassault Systèmes SE is the French-law European public software corporation behind the 3DEXPERIENCE platform, headquartered in Vélizy-Villacoublay and listed on Euronext Paris as DSY.PA. Its engineering, scientific modeling and simulation technologies support manufacturing, infrastructure and cities, and life sciences and healthcare. Current corporate leadership describes AI-powered 3D UNIV+RSES, data intelligence and virtual twins as core research and business priorities. Its healthcare relevance includes clinical-trial technology through Medidata, molecular and scientific software through BIOVIA, and prescription digital therapeutics through its actual investment in Click Therapeutics. Click’s March19,2025 issuer announcement states that Dassault Systèmes provided the entire Series C, with Medidata as its subsidiary strategic partner. This is a single parent corporate-buyer relationship rather than two independent checks. Cash allocation and individual subscription amounts are not established by the public converted-debt-inclusive regulatory total. The company’s public current management directory names twelve executives; its separate official board roster is preserved as governance rather than a VC partnership. Pascal Daloz became chairman and CEO on February21,2026 after Bernard Charlès stepped down from the chair and board. This legal software corporation is distinct from Dassault Aviation and controlling shareholder Groupe Industriel Marcel Dassault. Its brands, acquired subsidiaries, accelerator projects, commercial partners, public financing and corporate investments are not LP venture-capital funds, and no fund size or portfolio allocation is inferred from corporate revenue, market value or acquisition consideration.

Michael Schmelmer is vice chairman of Boehringer Ingelheim’s Board of Managing Directors, responsible for Group Functions. He previously led Finance and Group Functions and founded the BI X digital innovation laboratory. Earlier roles included the company’s CIO and technology leadership at Infineon. His qualifications include aerospace/mechanical engineering and industrial engineering.

Boehringer Ingelheim is an independent, family-owned global biopharmaceutical group founded in1885 inIngelheim am Rhein, Germany, developing human and animal health medicines. Its research and partnerships include mental health and neuroscience, immunology, respiratory disease, oncology and digital therapeutics. Shashank Deshpande chairs the Board of Managing Directors and leads Human Pharma; the current six-member executive directory covers Group Functions, Innovation, IT and Global Business Services, Finance and Animal Health. Hubertus von Baumbach chairs the Shareholders’ Committee following theJuly2025succession; he is no longer recorded as the current executive-board chair. The corporate group makes strategic investments and commercial collaborations. Click Therapeutics’ April2026announcement explicitly identifies Boehringer Ingelheim as its Series D strategic investor, alongside separately dedicated commercialisation funding whose amount is undisclosed. That corporate-brand transaction is not automatically allocated to the separately incorporated Boehringer Ingelheim Venture Fund GmbH or its portfolio. The group’s ultimate parent and individual operating subsidiaries are distinct legal entities: historic consolidated reports identify C.H.BoehringerSohnAG&Co.KG, while the globalwebsite imprint identifies publisher BoehringerIngelheimInternationalGmbH, MainzHRB21063. Neither publisher nor ultimateparent is assumed to be the exact cash subscriber when a financing source names only the group brand. The profile is a qualified corporate-group investment identity, distinct from retained Venture Fund investor5635. Research budgets, grants, collaboration milestone ceilings, sustainability expenditure and venture-fund corporate allocations are not new company funding rounds or external LPfund closes.

Shashank Deshpande chairs Boehringer Ingelheim’s Board of Managing Directors and leads its Human Pharma business. His chairman appointment took effect July1,2025. He joined the company in2012 and held commercial leadership roles inGermany and Japan, including Japan country managing director; he earlier worked at Sanofi in the United States and Capgemini. He studied business administration at the University of Hamburg. Current directory titles take precedence over older animal-health wording retained in regional career timelines.

Andreas Kinsinger serves as back office operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Ramin Shahnazary serves as senior back office operations manager & producer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Tahir Ropica serves as back office operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Vanessa Hartner serves as back office operations managerin at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Alexander Haja serves as head of hr & office management at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Alexandra Dobre serves as office manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Andreas Fakler is Companisto Investment Director, sourcing and supporting startups and representing the network on advisory boards including NIMMSTA. His earlier renewable-energy finance career included operations in California and North American expansion.

Anna Schlei serves as team lead community building at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Bogdan Schimbischi serves as programmer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Christoph Schweizer is Partner and Head of Investment at Companisto. He has more than two decades of venture-capital and business-angel financing experience, including a previous partnership at btov Partners.

Christos Pazaras serves as senior web developer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Cristian Irimia is Companisto’s Partner and CTO. He develops the platform’s technical infrastructure, software frameworks, scalable systems and data architecture.

Danae Fritsch serves as jr. customer relations managerin at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Daniel La Marca leads Companisto’s legal team, supporting financing transactions, investor interests and portfolio-company structuring.

David Rhotert co-founded Companisto and serves as Managing Director and CEO. His entrepreneurial and legal background includes building partycard, corporate legal work and mergers and acquisitions. He participates in Berlin entrepreneurship and innovation organisations.

Diar John serves as senior marketing managerin at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Florian Huber is a Senior Investment Manager at Companisto, identifying and supporting companies especially in southern Germany. He joined in April2022 after postgraduate economics study focused on crowdinvesting.

Hajredin Xhaka serves as team lead customer relations at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Henning Kircher serves as bilanzbuchhalter at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Janette Lenz serves as backoffice operations / office manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Justus Müller is Companisto Investment Manager, supporting startup investments and financing. His published background includes venture-capital and investment work and developing financial structures.

Lars Melberg serves as e-mail marketing manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Leon Geurten serves as team lead back office operations at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Leonardo Andreatta serves as office manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Liliana Leybovich serves as senior operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Luisa Nelius serves as projekt managerin marketing at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Maricel Toma serves as programmer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Marvin Brandt serves as onboarding manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Michael Weidemann serves as senior back office operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Nicky Hughes is Companisto Investment Director. He develops deal flow, evaluates opportunities and structures financings, with experience across medtech, green technology and digital businesses.

Robert Riedel serves as backoffice operations manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Robin Ghosh is a Senior Investment Manager at Companisto, joining in October2023. His work includes startup assessment, diligence, negotiations and investor engagement. He previously spent ten years at the German Aerospace Center, supporting innovation and technology transfer.

Sara Kohl serves as office manager at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Sarah Buge is Companisto’s Chief Operating Officer. She oversees operations, organisational development, cross-team processes and execution of strategy, drawing on several years within the business.

Selma Özdemir serves as customer relations managerin at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Sophie Schultheiss is published as Companisto Head of Marketing on parental leave. Her role remains source-qualified to that current directory status.

Tamo Zwinge co-founded Companisto with David Rhotert and serves as Managing Director. A lawyer with prior CMS experience, he leads legal structures and financing-model development. He studied law in Berlin and commercial law at Auckland and previously co-founded partycard.

Till Wedemann is Companisto Senior Legal Counsel, working on equity financing, negotiations and portfolio transactions.

Tim Weifenbach joined Companisto as Investment Manager in December2024. He brings experience in accelerator programmes, corporate innovation, digital health and investor relations, including co-founding a mental-health business.

Vlad Ionescu serves as programmer at Companisto, supporting the Berlin investment network’s company-financing and investor operations.

Companisto is a Berlin digital investment network and financing platform founded in 2012 by David Rhotert and Tamo Zwinge. It selects startups and growth companies, structures financing, pools investor interests and supports portfolio businesses. Its network includes private investors and business angels; investment opportunities span AI, biotechnology, medical devices, robotics and physical-world technologies. Published supported companies include Parkinson-care developer Portabiles HealthCare Technologies, HKK Bionics, AI wound-assessment developer cureVision, Virtonomy, DiaMonTech, AMERIA and CrystalsFirst. The platform operator is Companisto GmbH, registered at the Berlin-Charlottenburg court under HRB132811B, with Rhotert and Zwinge as managing directors. Securities intermediation is handled separately by Companisto Wertpapier GmbH, a bound intermediary operating under Effecta GmbH’s liability, identified in the firm’s legal notice with BaFin register80164077. Depending on the offering, members enter direct or indirect investment contracts with an issuer or a named participation entity; published terms mention Companisto Venture Capital GmbH and Companisto Beteiligungs GmbH & Co.KG. A financing attributed to the Companisto network therefore does not establish an investment of the same amount from the operator’s balance sheet. Its Angel Club and individual crowd campaigns are investment channels rather than verified closed pooled LP funds. The current public directory identifies40 people across investment, legal, technology, operations, customer support, marketing and community teams.

Sean Marett advises ClavystBio. He served on BioNTech’s management board from2012 to2024, working on fundraising, commercial partnerships and expansion, and previously held commercial positions at Pfizer and GSK.

Ethan Jung Ryun Park is a ClavystBio director and a Temasek managing director. His background includes healthcare and life-sciences investing across Europe, the Middle East, Africa and Southeast Asia, following earlier work at SK Corporation.

Steve Krognes is a director of ClavystBio with senior finance and transaction experience in biotechnology. His previous positions include chief financial officer at Denali Therapeutics and Genentech and global mergers-and-acquisitions leadership at Roche.

Samantha Yeo manages finance and compliance at ClavystBio. She previously worked in KPMG’s governance, risk and advisory team, followed by finance and operational work supporting early-stage ventures at Lightstone Ventures.

Gladys Yeo is ClavystBio’s infrastructure manager and oversees the Node1 laboratories and offices. Her background includes diagnostic-laboratory operations and a biomedical science degree from Aston University.

Ewen Poh manages human resources at ClavystBio, covering recruitment, talent management and HR operations. She previously supported early-stage biotech businesses as an HR partner and worked in executive search.

Jamie Wong is ClavystBio’s finance director, responsible for financial systems, governance and support to portfolio companies. She previously held finance-director responsibilities at Temasek International.

Nge Hwee Ng is a founding-team member and business development and operations lead at ClavystBio. She previously worked in Temasek’s Portfolio Development Group and in corporate finance and valuations at PwC.

Regis Ong leads infrastructure at ClavystBio, including its laboratory facility at Singapore Science Park. He previously served as technical head at Fuchs Singapore and helped establish Life Science Incubator.

Jason Ng is ClavystBio’s legal lead, advising its venture-building and investment activities. His career includes Singapore’s Ministry of Law and private- and social-sector legal work, with extensive experience supporting startups and transactions.

Vincent Lai is vice president for cybersecurity and IT at ClavystBio. His responsibilities cover information security, digital infrastructure and data governance, drawing on experience in IT, privacy and regulated business environments.

Grace Chua manages community engagement at ClavystBio, organizing life-sciences events and connections. She previously developed partnerships and youth programmes at Singapore’s National Environment Agency.

Carol Chan is ClavystBio’s executive assistant and office manager. She supports executive schedules and office operations, following administrative work with Eric Salmon & Partners and DTCA executive-search businesses.

Marcus Tan is a senior associate at ClavystBio. He previously managed Danaher’s Asian venture activity in genomic medicine, bioprocessing and diagnostics, and worked on investments at Heritas Capital.

Charles Yiliu Zhang is an assistant vice president in ClavystBio’s therapeutics team. His background combines biotech venture investing, patent work and postdoctoral research at A*STAR’s Institute of Molecular and Cell Biology. He earned a cell and molecular biology doctorate at NUS.

Ning Mao is a senior associate at ClavystBio focused on investment and venture creation. Earlier work includes early-stage biotech investing, portfolio-company operations and business development, and consulting for life-sciences clients.

Cheryl Tan is an assistant vice president for medtech at ClavystBio. She brings clinical experience to healthcare investment evaluation and previously worked with Temasek’s life-sciences investment team.

Johnny Ng is an assistant vice president in ClavystBio’s therapeutics team. He previously worked on life-sciences investments at Xora Innovation and led a discovery programme at Singapore’s Experimental Drug Development Centre.

Yingmin Wang is a medtech director at ClavystBio. Her career spans research at A*STAR, venture and business development at Singapore’s Economic Development Board, and leadership of Applied Materials’ Southeast Asian regional and technology offices.

Yvonne Koh is a therapeutics director at ClavystBio. Her background includes early-stage venture diligence and programme management at Lightstone Ventures and innovation-policy work as a deputy director at Singapore’s National Research Foundation.

Anselm Tan leads medtech at ClavystBio, including digital-health ventures. He formerly headed venture capital at Heritas Capital and launched Asia-Pacific health-technology investments as a partner at Philips Ventures.

Kang Lin Ong is chief financial officer of ClavystBio. His earlier finance leadership includes Luye Medical Group and Docquity. He holds a finance doctorate from EDHEC, a Wharton MBA and CFA qualification.

Wen Qi Ho leads therapeutics at ClavystBio, investing in and building healthcare companies. She previously led Lightstone Ventures’ Singapore investment and operating activities, covering biotechnology and medical devices.

Khoo Shih is ClavystBio’s chief executive and a founding-team member. She previously led life-sciences investing at Temasek and worked in venture investment at UOB Venture Management. Her scientific training includes a genetics and development doctorate from UT Southwestern.

AVM SGR is an Italian alternative investment manager operating private equity and venture capital funds. It invests in and helps develop businesses through operating support, expansion and acquisitions, with strategies covering essential goods and services, robotics, cybersecurity, digital technology and impact investing. It is the regulated EuVECA manager of Rialto I and other dedicated funds. Current legal identity is AVM SGR S.p.A., Italian tax/VAT number 09046930963; historical issuer releases use AVM Gestioni SGR.

Rialto Ventures is a European venture investment team that backs technology companies led by European founders and helps them expand internationally, particularly into the United States. It focuses on Series A B2B businesses spanning developer infrastructure, robotics, advanced manufacturing, cybersecurity, AI, cloud software and technology-enabled healthcare. Its Rialto I EuVECA fund is legally established and managed by AVM SGR; Rialto provides the dedicated investment team and operating support.

Vantage Asset Management is an Australian private equity investment manager that gives wholesale investors access to lower and middle-market businesses in Australia and New Zealand through diversified fund-of-funds, secondary investments and direct co-investments. It selects private equity managers pursuing growth, buyout and turnaround strategies across sectors including software, technology and healthcare. The legal manager is Vantage Asset Management Pty Limited, ACN 109671123, AFSL 279186.

Oversees AVM operations and selected portfolio-company activities.

Academic and business adviser with experience in investment, management and social-impact projects; no precise AVM job title is stated on the published roster.

Operating executive and investor with extensive experience building international clinical-services businesses.

Leads people, workplace and culture activities and supports the firm’s internal operations.

Investment and operating professional with experience in industrial restructuring, mergers and acquisitions.

Private-equity investor with an operating, finance and business-management background who co-founded AVM with Giovanna Dossena.

Analyst working on leveraged-buyout and venture-capital transactions.

Former PwC financial-services partner with investment-management, assurance, transaction and governance experience.

Oversees fund accounting, reporting, investment administration, audit and tax compliance, following audit work at PwC and EY.

Private-equity investor and fund manager who co-founded Odyssey Private Equity and previously held leadership roles at CHAMP Ventures, Pollination and the Australian Investment Council.

Investment-team associate with a finance and strategic business-analysis background.

Evaluates private-equity opportunities and monitors portfolio investments, following work at Carlyle in London and PwC.

Sources and assesses investment opportunities, with prior strategy-consulting and corporate-law experience.

Investment professional with experience in healthcare and automotive business analysis and training in law and management.

Investment and strategy professional whose background includes consulting, financial institutions and entrepreneurial ventures; no precise AVM job title is stated on the published roster.

Supports operational processes and control activities, following consulting work.

Advises on business development, international expansion and transformation, drawing on supply-chain and logistics experience.

Sources, evaluates and executes private-equity investments and helps structure fund solutions for Australian and international investors.

Founded Vantage in 2004 and oversees its private equity investment programs, following development-capital and private-equity work at St George Bank.

Supports investor communications, reporting and registry relationships, following fund-operations work at Automic Group.

Leads investment-team activities across primary funds, co-investments and secondaries, with prior private-equity experience in Australia and the United Kingdom.

Experienced Australian company director and legal adviser, formerly chief executive of Sydney’s successful Olympic bid.

Private-equity and accounting professional with transaction, audit and corporate-governance experience.

Aqua Membranes develops and manufactures reverse osmosis membrane elements for industrial water purification and reuse. Its patented Printed Spacer Technology prints three-dimensional features directly onto membrane surfaces, replacing the conventional plastic mesh spacer inside spiral-wound elements. The redesigned flow channels reduce pressure losses and fouling, helping operators lower energy use, increase water recovery and reduce cleaning interruptions. Its membrane elements fit existing reverse osmosis equipment, allowing facilities to upgrade filtration performance without replacing the whole system. The company serves semiconductor manufacturing, mining, power generation, food and beverage processing and water recycling, and provides engineering consultation, system-design software and an operating-cost calculator.

Verix, operated by Virtualness Corp., provides digital credential issuance, verification and engagement software for organizations and brands. It uses generative AI to help design certificates, badges and awards, then records credentials on blockchain and supplies QR codes and Open Badge verification so recipients can demonstrate authenticity and ownership. Organizations can issue learning and professional credentials, manage memberships and compliance renewals, recognize achievements, support event registration and ticketing, and authenticate products. Credentials can include rewards and multimedia, evolve as recipients complete further activities and be shared on LinkedIn. Administrators track redemption and engagement and connect credential workflows with existing systems. The company originally launched as Virtualness, a creator-focused Web3 platform.

Published name: Ben Yu. Adviser to Verix (Virtualness). Existing same-name identities are preserved; no identity merge is asserted without corroboration.

Published name: Bobby Napiltonia. Adviser to Verix (Virtualness). Existing same-name identities are preserved; no identity merge is asserted without corroboration.

Published name: Namrata Ganatra. Adviser to Verix (Virtualness). Existing same-name identities are preserved; no identity merge is asserted without corroboration.

Taika3D is a Finnish software company automating the design and production workflow for custom orthotic and prosthetic devices. TaikaCapture collects patient 3D scans and clinical prescriptions through mobile scanning and web forms. TaikaCreate uses AI, 3D machine vision and configurable design rules to prepare and align scans, generate patient-specific orthotic models and let designers review them before manufacturing. The cloud platform supplies production-ready files for 3D printing or CNC milling and helps manufacturers manage orders, users and milling toolpaths. Founded in 2018, the Espoo-based company serves orthotics and prosthetics laboratories and manufacturers.

UpNano is a Vienna-based manufacturer of high-resolution 3D printing systems founded in 2018 from research at TU Wien. Its NanoOne printers use two-photon polymerization to create polymer structures from submicrometer features to centimeter-scale parts. The company combines printers, operating software, optimized resins and printing services for optics and photonics, microfluidics, micromechanics, sensors and medical devices. NanoOne Bio supports printing in a native cell environment for biofabrication and tissue-engineering research, while its Upscale service produces polymer microparts for customers. UpNano GmbH operates a US subsidiary, UpNano US Inc., in Cambridge, Massachusetts.

Professor at TU Wien and head of its 3D Printing and Biofabrication research group. The company names him as a founder and scientific adviser.

Named CFO in the company’s management-photo caption. The same photo was uploaded September 1, 2026 and appears on the current About page; the caption is on an older article and no appointment date is asserted.

Optics and electronics researcher identified by UpNano with A*STAR IMRE and Singapore’s National Semiconductor Translation and Innovation Centre.

Industrial designer and orthotics/prosthetics CAD specialist. This staff role is published in a dated company interview; continued appointment in October 2026 is not independently confirmed.

Co-founder and chief executive of UpNano, named on its current company page.

Additive manufacturing researcher identified by UpNano as Director of the Center of Additive Manufacturing and Design Innovation at the University of Texas.

Co-founder responsible for operations, named in UpNano’s founding-team description.

Named VP US in the company’s management-photo caption. The same photo was uploaded September 1, 2026 and appears on the current About page. The company’s July 2022 announcement describes her recruitment from Harvard’s Office for Technology Development.

Cell and tissue research specialist named on UpNano’s scientific advisory board.

Named CBO in the company’s management-photo caption. The same photo was uploaded September 1, 2026 and appears on the current About page; its explanatory caption is on an older financing article, so the precise appointment date is unknown.

Professor at the Wake Forest Institute for Regenerative Medicine, named on UpNano’s advisory board.

Works on systems architecture, design for manufacturing and the standard product platform. His company biography describes digital manufacturing of medical devices and a visiting professorship at Newcastle University.

Maastricht University professor and MERLN Institute management member, named on UpNano’s scientific advisory board.

Co-founder responsible for technology, named in UpNano’s founding-team description.

Software developer and team leader working on 3D design solutions; previously worked in electroluminescent-display product development.

IT professional with software-consulting and SAP Business One experience. This staff role comes from a dated company interview; continued appointment in October 2026 is not independently confirmed.

Production technology and product development specialist involved in establishing Taika3D’s design-automation platform.

Orthotics industry executive whose company biography describes clinical sales teams, custom manufacturing and NHS experience.

Marketing and communications professional with experience in orthopedic and aesthetic medical devices and international trade.

Technology entrepreneur with experience in electronic circuit design, industrial 3D imaging and automated CAD software.

Software developer with a business information technology degree and game-development experience. The company interview describes joining Taika3D in 2018; continued appointment in October 2026 is not independently confirmed.

ARIS Occitanie is the Agence Régionale des Investissements Stratégiques, a French mission-driven investment company supporting industrial sovereignty, local economic development and ecological transition in the Occitanie region. Created institutionally in March 2021 and incorporated as an active SAS on July 1, 2021 (SIREN901805630), it has public and private shareholders and offices in Toulouse and Montpellier. ARIS makes minority equity and quasi-equity investments, mainly alongside other investors, in companies based in Occitanie or planning to locate there. Its latest mission report describes typical EUR0.5M–1.2M tickets, approximately five-year holding periods and priorities spanning low-carbon energy, mobility, health, agroecology, digital transformation and strategic industries. Relevant portfolio businesses include AI-powered visual-recognition company LTU, autonomous agricultural robotics company Naïo Technologies and auditory-neuroscience biotechnology company Cilcare. Since February2023, the separate mostly public asset manager OCCTE has provided operational management under a service contract; the ARIS legal investment company remains the named Cilcare shareholder. Its latest report names six leadership and investment professionals, fifteen external decision-committee representatives and a mission reference; official registry records additionally name two management-board members. The 2025 report lists twenty portfolio companies, EUR32.7M deployed and EUR41M investment capacity, with a EUR50M investment ambition for2030. These are operating metrics and targets. A separate EUR4.1M corporate equity capital raise was announced by the Region on March14,2024; no outside-LP fund close is established. ARIS Occitanie is distinct from ARIS software businesses, Aris Water Solutions and unrelated similarly named investment companies.

Head of Investments at ARIS Occitanie, serving in the investment team provided by external operator OCCTE. The latest mission report describes the investment-management hire in 2025.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Bpifrance. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Nubbo. This affiliation is documented in the 2025 report published in July 2026.

Registered management-board member of ARIS Occitanie. ARAC Occitanie’s published organizational sources identify him as its director general, providing regional infrastructure and development experience.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Captain Watt. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from AD’OCC. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Bpifrance. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from CCI Occitanie. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Caisse d’Épargne Midi-Pyrénées. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Magellim. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Région Occitanie. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Banque des Territoires. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Groupama d’Oc. This affiliation is documented in the 2025 report published in July 2026.

Named by ARIS’s latest mission report as a permanent decision-committee representative from AREC. This affiliation is documented in the 2025 report published in July 2026.

Registered management-board member of ARIS Occitanie. AD’OCC’s official 2022 activity report also identifies him as the regional economic-development agency’s director general; that external role is source-dated.

Named by ARIS’s latest mission report as a permanent decision-committee representative from Caisse d’Épargne Languedoc-Roussillon. This affiliation is documented in the 2025 report published in July 2026.

Administrative and financial director at ARIS since February 2023. Previously managed real-estate fund finances at Midi 2i and worked on financial management for Crédit Agricole Services Immobiliers. Holds a accounting, control and audit degree from Toulouse School of Management. OCCTE’s current team also names him administrative and financial director.

Named by ARIS’s latest mission report as a permanent decision-committee representative from APRC. This affiliation is documented in the 2025 report published in July 2026.

Director of ARIS since February 2023, with experience in regional innovation, sustainable development and technology businesses. Previously worked in audit at PwC and transaction services at KPMG, co-led a connected-vehicle software company, and managed innovation programs at Toulouse Métropole. Holds a finance and audit degree from Paris Dauphine. OCCTE’s current team names him managing director and chief compliance and internal control officer (RCCI).

Chair of ARIS Occitanie’s supervisory board, responsible for strategic oversight of the regional investment company.

President of ARIS Occitanie’s management board, overseeing the regional investment company’s strategy and investment decisions. OCCTE’s current team names him president and chairman. Its professional biography describes experience in energy-transition investing, territorial development and public-private partnerships, including prior SHEM-Engie and Compagnie Nationale du Rhône roles.

Named by ARIS’s latest mission report as a permanent decision-committee representative from ARAC. This affiliation is documented in the 2025 report published in July 2026.

Investment analyst supporting ARIS through its external operator OCCTE. ARIS’s latest mission report names her in the investment team and states that the analyst joined in early 2026; further career history is not publicly established in that source.

Charles Wiebe is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Kara Walker is published by University of Vermont Health as Board Secretary. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Betsy Vicencio is published by University of Vermont Health as Board Vice Chair, Chair of Compensation Committee and Chair, Audit & Risk Management Committee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Christine Peters is published by University of Vermont Health as Chair, Strategic Planning Committee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Richard Page is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Heidi Melbostad is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Robert Main, Jr. is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Dain LaRoche is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Kevin Hart is published by University of Vermont Health as Trustee. A retired Alice Hyde Medical Center executive with procurement, facilities and support-services experience; retired in2015 after three decades there. He is distinct from the existing same-name Curie.Bio strategic-finance professional and the entertainer.

Sarah Harm is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Erica Metzger Hare is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Tom Golonka is published by University of Vermont Health as Board Chair and Chair, Governance Committee. Thomas J. (Tom) Golonka is an investment-management professional and CFA/CFP charterholder; the health-system board biography describes work at Silverlake Wealth Management and Vermont pension governance.

Kim Farnham is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Dominic Eisinger is published by University of Vermont Health as Chair, Investment Committee. A biotechnology executive and entrepreneur with protein-biomarker testing and clinical-development experience; chairs the system’s Investment Committee. The own board biography names historical company roles, which are not separately asserted as current jobs.

John Dwyer is published by University of Vermont Health as Chair, Finance Committee. A credit-union executive and accountant, published as president and CEO of EastRise Credit Union. His university-health role is finance-committee governance rather than a personal portfolio check.

Victoria Duley is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Joseph Donnery is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Jesse Bridges is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Steven Cacchio is published by University of Vermont Health as Trustee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Dragos Banu is published by University of Vermont Health as Chair, Quality & High Value Care Committee. The current own board roster records a community governance affiliation. Trustees are unpaid volunteers with oversight responsibilities; neither board service nor a committee appointment implies a personal equity check.

Judy Schaechter is published by University of Vermont Health as Chief of Pediatrics, Golisano Children’s Hospital. A pediatrician and academic leader, previously at CDC, the American Board of Pediatrics and University of Miami; began the UVM pediatrics chair role July1,2026.

Joseph Pierson is published by University of Vermont Health as Chair, Department of Dermatology. A dermatologist and educator with previous U.S. Army medical leadership and active-duty service.

Jeffrey Peipert is published by University of Vermont Health as Chair, Department of Obstetrics, Gynecology, and Reproductive Sciences. A physician-scientist and academic specializing in reproductive health, obstetrics and gynecology.

Claude Nichols is published by University of Vermont Health as Chair, Department of Orthopedics and Rehabilitation. An orthopedic surgeon whose specialty includes sports medicine, knee and shoulder surgery, and traumatic injuries.

Mitchell Norotsky is published by University of Vermont Health as Chair, Department of Surgery. A cardiothoracic surgeon and academic experienced in complex coronary, pulmonary and thoracic surgical care.

Shalina Nair is published by University of Vermont Health as Chair, Department of Family Medicine. A family physician and academic interested in prevention, chronic disease, eConsults and operational quality improvement.

Nataniel Lester-Coll is published by University of Vermont Health as Chair, Radiation Oncology. A radiation oncologist and clinical-trial researcher treating genitourinary cancers and tumors of the brain and central nervous system.

Andrew Goodwin is published by University of Vermont Health as Interim Chair, Department of Pathology and Laboratory Medicine. A clinical pathology academic and medical director working on thrombosis and hemostasis; department chair appointment is explicitly interim.

Anne Dixon is published by University of Vermont Health as Chair, Department of Medicine. A physician-scientist researching asthma and pulmonary disease associated with obesity and metabolic dysfunction.

Kristen DeStigter is published by University of Vermont Health as Chair, Department of Radiology. A radiologist researching sustainable and affordable diagnostic imaging in rural and resource-constrained settings.

Peter Calabresi is published by University of Vermont Health as Chair, Department of Neurological Sciences. A neurologist and multiple-sclerosis researcher whose work concerns precision medicine and neuroimmunology.

Richard Bounds is published by University of Vermont Health as Interim Chair, Department of Emergency Medicine. An emergency physician and educator who helped establish Vermont’s emergency-medicine residency; current chair title is explicitly interim.

Rebecca Aslakson is published by University of Vermont Health as Chair, Department of Anesthesiology. A critical-care anesthesiologist and palliative-care physician-scientist researching patient- and family-centered care.

Robert Althoff is published by University of Vermont Health as Chair, Department of Psychiatry. A child and adolescent psychiatrist researching emotional self-regulation, also a Larner College of Medicine academic.

Marc Kosak is published by University of Vermont Health as President & Chief Operating Officer (Central Vermont Medical Center). A hospital operations executive previously at Greenwich Hospital and Yale New Haven Health.

Christine Werneke is published by University of Vermont Health as President & Chief Operating Officer (Home Health & Hospice). A community and population-health leader who became Home Health & Hospice president and COO in2023.

Bob Ortmyer is published by University of Vermont Health as President & Chief Operating Officer (Elizabethtown Community Hospital Porter Medical Center). A hospital executive with a long WellSpan career; joined Elizabethtown in2021 and also took on Porter leadership inMay2024.

Michelle LeBeau is published by University of Vermont Health as President & Chief Operating Officer (Champlain Valley Physicians Hospital Alice Hyde Medical Center). A health-care leader with a nursing background, leading Champlain Valley Physicians Hospital and Alice Hyde Medical Center.

Jessica Moschella is published by University of Vermont Health as Senior Vice President, High Value Care, UVM Health. The health-system executive responsible for its High Value Care portfolio; this operating leadership position is not venture-fund management.

Stephen Leffler is published by University of Vermont Health as Chief Executive Officer, UVM Health; President & Chief Operating Officer, UVM Medical Center. An emergency physician and medical educator with more than thirty years at the medical center. Appointed permanent system CEO January2026 after interim service fromOctober2025; older SunilEappen CEO listings are superseded.

Eric Miller is published by University of Vermont Health as Senior Vice President, General Counsel, UVM Health. The system’s senior legal executive. His UVM identity is distinct from the existing same-name Arizona Tech Investors professional; no unrelated investment roles or images are merged.

Ginger Lubkowitz is published by University of Vermont Health as Chief Development Officer of Academic Health Sciences, UVM Health & UVM Foundation. The health-system directory identifies a joint Academic Health Sciences development role involving UVM Health and the separate UVM Foundation. Its card contains apparently mismatched biographical text, which is not copied or treated as this individual’s education.

Brad Krompf is published by University of Vermont Health as Executive Director, UVM Health Medical Group. A health-care operations leader experienced in consulting, ambulatory surgery and multidisciplinary clinical services.

Carrie Howard-Canning is published by University of Vermont Health as Senior Vice President, Chief Nursing Executive, UVM Health. A nurse and senior nursing executive whose background includes decades of clinical and leadership work across several UVM hospitals.

Mary Broadworth is published by University of Vermont Health as Chief Human Resources Officer, UVM Health. A human-resources executive with experience in organizational transformation, integration and process improvement; joined the medical center in2020 and led system HR transformation from2023.

Richard Vincent is published by University of Vermont Health as Executive Vice President, Chief Financial Officer, UVM Health. A finance executive with more than three decades at the health system, overseeing integration of financial and administrative operations. The FY2023 tax filing also identifies him in venture-subsidiary governance; it does not disclose a personal Cilcare check.

Ramsey Herrington is published by University of Vermont Health as Chief Physician Executive of UVM Health; President and CEO, UVM Health Medical Group. An emergency physician and medical educator who helped establish the system’s emergency-medicine residency and academic department.

University of Vermont Health is the current public brand of The University of Vermont Health Network Inc., a not-for-profit, tax-exempt Vermont corporation operating an integrated academic and community health system in Vermont and northern New York. The legal corporate identity is verified by its own audited FY2024 financial statements and IRS Form990, EIN45-2880726. It is affiliated with the University of Vermont’s Larner College of Medicine and College of Nursing and Health Sciences but is distinct from the university, its endowment, UVM Foundation, the medical-center foundation and constituent hospital legal entities. The system provides hospital, specialty, community, home-health and hospice care and supports clinical research and academic medicine. Its current own leadership pages publish executives, partner-hospital presidents, clinical department chairs and22 trustees; these are institutional operating/governance roles, not an investment-fund employee directory. Stephen Leffler became permanent system CEO on January2026 after interim service fromOctober2025, superseding former CEO SunilEappen. The public roster includes neurological-sciences chair PeterCalabresi, psychiatry chair RobertAlthoff, and executives overseeing high-value care and clinical integration. The system has mission-aligned strategic investment activities. Cilcare’s April18,2024 issuer announcement explicitly identifies University of Vermont Health Network as a new shareholder in its auditory-science and biomarker programme. Its December4,2024 financing announcement names UVM Health Capital among historical investors in the latest EUR21million tranche of an aggregate EUR40million SeriesA. The shared health-system ecosystem is supported by the issuer narrative, but the exact legal vehicle behind the December brand is not disclosed; no automatic alias merge or substitution of the parent is made for that financing. The FY2024 accounts distinguish UVM Health Network Ventures Inc., a for-profit investment holding company, from Health Network Ventures Holding LLC, a separate501(c)(3) investment holding entity. They are not equated with one another or with the parent. A primary2019 BioFactura release confirms an actual investment by the network’s ventures arm and names ChrisJones as Director of Venture Investments. The 2023tax return names then-officers SunilEappen and RichardVincent in venture-subsidiary governance; those disclosures are historically dated. Regulatory assets, operating revenues, restricted funds, venture-holding asset values, budgets and foundation donations are not private-LP fund closes or individual issuer tickets. No invented venture vehicle, current branch team, cash amount or parent/subsidiary duplicate investment is added.

Edward Hu is a director/member of 6 Dimensions Capital Limited in its March2026 legal filing. The WuXi-hosted June2023 BOLD event supplies his authentic portrait and then-current vice-chairman affiliation; that event title is historical.

WuXi AppTec founder Ge Li was identified as founder and chairman in 6 Dimensions’ December2017 close announcement and remains a legal director/member in its March2026 filing. This person is distinct from the Swinburne communications researcher of the same name. WuXi AppTec current published biography: Scientist and entrepreneur leading the company since2000, pioneering its integrated open-access drug research/development/manufacturing platform. Organic chemistry PhD from Columbia University and chemistry degree from Peking University. Current own director filing identifies chair and CEO. Existing 6Dimensions role and authentic portrait preserved.

Xiaoliang Sunney Xie is published by 6 Dimensions Capital as Adviser (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The card’s external institutional title belongs to the adviser’s outside organization, not a 6 Dimensions executive office.

Jason Sun is published by 6 Dimensions Capital as Adviser (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The card’s external institutional title belongs to the adviser’s outside organization, not a 6 Dimensions executive office.

Quanlu Zheng is published by 6 Dimensions Capital as Adviser (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The card’s external institutional title belongs to the adviser’s outside organization, not a 6 Dimensions executive office.

Allen Chao is published by 6 Dimensions Capital as Adviser (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The card’s external institutional title belongs to the adviser’s outside organization, not a 6 Dimensions executive office.

Ching Zhu is published by 6 Dimensions Capital as Affiliate Member (undated published roster); Director and Member, Qingsheng Zhu (March2026 filing). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Wei Li is published by 6 Dimensions Capital as Affiliate Member (undated published roster); Director and Member (March2026 filing). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Norman Chen is published by 6 Dimensions Capital as Venture Partner (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Dong Wu is published by 6 Dimensions Capital as Venture Partner (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Hongye Sun is published by 6 Dimensions Capital as Venture Partner (undated published roster). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Richard Li is published by 6 Dimensions Capital as Legal Director. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Vivian Li is published by 6 Dimensions Capital as Finance-VP. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Jin Wang is published by 6 Dimensions Capital as VP Finance. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Deep experience in VC/PE finance area, served various cross border venture funds Ex-Senior Manager at Standish Management Ex-Audit Manager from Deloitte, specialized in Investment Company industry

Christina Chung is published by 6 Dimensions Capital as Chief Financial Officer. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Based in Hong Kong, Ms. Christina Chung is the Chief Financial Officer of Frontline BioVentures. Christina has over 13 years of hands-on professional experience in the finance and accounting field. Prior to Frontline BioVentures, Christina was the Associate Director of Fidelity Growth Partners Asia (Fidelity) between 2009 to 2013, responsible for the finance reporting, valuation and portfolio management activities.

Jia Sun is published by 6 Dimensions Capital as Associate. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Leo Yan is published by 6 Dimensions Capital as Senior Associate. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Mr. Leo Yan joined Frontline BioVentures in 2016 with over 5 years of investment experience in healthcare industry. Before joining Frontline BioVentures, Mr. Yan was Senior Investment Manager of Global Healthcare Service Team in Fosun Health Holdings, a department under Fosun International (00656.HK).

Corrine Chen is published by 6 Dimensions Capital as Vice President. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ms. Corrine Chen joined Frontline BioVentures in 2017 with over 5 years of investment and professional service experience. Ms. Chen started her career in KPMG, leading and participating in several annual audit engagements of China and HK listed companies, and several NASDAQ/NYSE/HKEX IPO audit engagements as an Assistant Manager in audit department.

Jie Zhang is published by 6 Dimensions Capital as Vice President. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ex-Principal Scientist, Infectious Disease Research, WuXi AppTec Ex-Institute Pasteur, CNRS France MS in systemic biology in University of Paris PhD in Pathology and Cell Biology from University of Montreal

Jianwei Yuan is published by 6 Dimensions Capital as Vice President. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ex-Senior Investment Manager for Medical Device M&A at Fosun Pharma Ex-Scientist, Pharmaceutical R&D in CNS at Glaxo Smith Kline MS from Shanghai Institute of Biological Sciences, MBA from Fudan University, CFA Level I

Wei Zhao is published by 6 Dimensions Capital as Executive Director. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ex-Senior Life Sciences Specialist, L.E.K. Consulting Postdoctoral fellow, Massachusetts Eye and Ear Infirmary / Harvard Medical School PhD in Neuroscience, Northwestern University

Hannes Smárason is published by 6 Dimensions Capital as Senior Managing Director. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Colin Wang is published by 6 Dimensions Capital as Partner. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment.

Qin Xie is published by 6 Dimensions Capital as Partner. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. The own website publishes Qin Xie as Partner and also retains an older Executive Director card. Its older HTML interleaves another person’s qualifications; those qualifications are not attributed to Qin.

Rebecca Zhu is published by 6 Dimensions Capital as Partner. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Ms. Zhu joined Frontline BioVentures in 2014 with over 6 years of investment experience in healthcare industry. Prior to Frontline BioVentures, Ms. Zhu was Analyst of Power Pacific Corporation (member of Power Corporation of Canada), specializing in research and investment in publicly traded healthcare companies listed in Shanghai, Shenzhen and Hong Kong Stock Exchange.

Erdong Hua is published by 6 Dimensions Capital as Partner. The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Mr. Hua is a Partner of Frontline BioVentures. He joined the team in 2012 with over 10 years of dedicated experience in medical/healthcare, venture capital investment and financial industries.

Leon Chen is published by 6 Dimensions Capital as CEO & Founding Partner; Director and Member (March2026 filing). The accessible roster is undated and contains historical Frontline/WuXi context; this is not independent verification of current2026 employment. Dr. Chen is Founder and Managing Partner of Frontline BioVentures. Leon has over 20 years of experience in the Life Sciences industry in China and the U.S. as a venture capitalist, senior management executive, entrepreneur, and scientific inventor.

Kona Venture Partners LLC is a Seoul-based Korean venture capital manager established in 2018. It invests in game development and other content businesses and has expanded its investment focus to artificial intelligence and technology. The firm manages venture investment partnerships and offshore funds, supporting companies from their early stages through growth. It operates the KRW120 billion Kona Venture Fund VII, launched with Nexon Partners and South Korea’s Ministry of Culture, Sports and Tourism to back independent game studios from seed through Series A and develop globally scalable intellectual property using advanced technologies, including AI.

Chief executive of Kona Venture Partners LLC, as named in the Korean Venture Capital Association’s current English firm directory. Korean name: 최화진. Also rendered Hwa-Jin Choi.

Abhyuday Hari Prasad joined Sabi as a software engineer in 2026. His firstperson announcement identifies its Palo Alto brain-computer-interface work and founders Rahul Chhabra and Atmadeep Banerjee. He studied engineering at Dayananda Sagar College and participated in IASNLP2026 language-processing research.

Ojasvi Yadav previously built AI models, pipelines and product software at Sabi. His current personal site identifies independent work on The Learning Harness, following AI leadership at Writesonic and Dukaan and research at V-SENSE.

Bhavya L is a publicly named Sabi researcher with an interest in neural decoding.

Guruprasad Kudte appears in Sabi’s published launch research-team roster; exact operating title is unpublished.

Mohammed Raasith is publicly identified with Sabi’s Bengaluru research team and cognitive-neuroscience research.

Ritika Khanna works with Sabi; her professional biography describes computational neuroscience, EEG processing and AI.

Sameeha Maheen appears in Sabi’s published Bengaluru launch research-team roster; exact operating title is unpublished.

Varsha V. is publicly identified with Sabi in Bengaluru and its launch research-team roster.

Vidyun Mittal is a publicly named Sabi researcher with neuroscience and biomedical research experience.

Sud PME Croissance is a French direct investment company established in 2009 and headquartered in Montpellier. The active legal entity is a société par actions simplifiée registered as SIREN 512778465 and LEI 969500E7P67ZEBJ6UP13. Its filed statutes authorize direct equity participation in industrial, commercial and other businesses, and identify Hervé Lemaitre as president. Cilcare names it as an existing investor supporting auditory biotechnology and clinical development, including its April and December 2024 financing announcements. This is a corporate investment holding company; an external fund manager or separate LP fund is not established by the available primary evidence. It is distinguished from IRDI/SORIDEC vehicles and Banque Populaire du Sud’s separately named Sud Croissance. Its reported share capital is corporate capital rather than a fund close.

Abhinit Ranjan heads Sabi operations and published its April2026 launch announcement.

Eddu Israel is identified as Sabi’s data analyst lead in its public launch-team announcement.

Hervé Jean Lemaitre is the legally published president of Sud PME Croissance, the Montpellier direct investment company registered as SIREN512778465. The company’s formation notice and its certified April2022 decisions name him in that capacity. This affiliation is supported by legal filings; a broader career biography and an authentic individual portrait have not been established. He is not identified with the similarly named neuroscience researcher or other unrelated namesakes.

Bhavya Mandali was featured by Virtual Therapeutics in its March29,2024 Celebrating Women in Tech employee interview as a VR software engineer. She describes studying computer engineering, pursuing a master’s degree after discovering virtual reality, and combining software engineering with creative work. She reported about ten years in the software industry and discussed returning to engineering after parenting-related career breaks. The own article publishes her original portrait. Her role is source-qualified as reported in2024 rather than assumed current employment.

Marissa Bertorelli was named a director of Virtual Therapeutics Corporation in its May31,2024 primary SEC tender roster. At that time she was a Polaris Partners principal, having joined in2019, focused on healthcare investing. Prior to Polaris she traded equity derivatives in Goldman Sachs’ Securities Division. She holds an MBA from Stanford, where she was an Arbuckle Fellow, and BS in Finance from Boston College. Her2024 conference-organizer biography corroborates her Polaris career and publishes an authentic portrait. This is a last-confirmed2024 parent board appointment; no current Polaris employment or complete2026 parent board is asserted.

Ben Wiegand, PhD, was an independent director of Virtual Therapeutics Corporation in its May31,2024 primary legal roster. That filing identifies him as Lore Health Chief Scientific Officer sinceJune2023 and a founding partner of Connected World Without Disease Accelerator since2022, following Optum Labs SVP R&D2020–2022 and25years of increasingly senior Johnson & Johnson roles. Those included Janssen global leadership of World Without Disease Accelerator2017–2020 and Disease Interception Accelerator2014–2017. He has a chemistry undergraduate degree from the University of Illinois and MA/PhD in Physical Chemistry from Harvard. The SEC calls his undergraduate degree BA while an earlier J&J biography calls it BS; the degree field is retained without resolving that conflict. Current parent board service and an authentic original portrait are not verified.

Virtual Therapeutics Corporation is a privately held digital-health company incorporated in Delaware on May29,2015 and based in Kirkland, Washington. Its current vthera.com website describes immersive mental-health and mental-fitness products: Breakthrough combines interactive media, intelligent real-time feedback and AI-based analysis, while Bloom is its virtual-reality experience for stress, anxiety, resilience and sleep. Its ADHD cognitive-medicine products EndeavorRx and EndeavorOTC are developed by acquired subsidiary Akili; the parent completed Akili’s take-private acquisition on July2,2024. This acquisition at USD0.434 per Akili share was a purchase of existing securities, not a new financing round for either issuer. The May31,2024 primary SEC tender filing states that Polaris Partners and ClavystBio completed separate non-controlling minority equity investments in Virtual Therapeutics on May24,2024, for undisclosed amounts. Founder Daniel J. Elenbaas retained majority shareholder control; the two institutional investors jointly appointed one director. The four named officers/directors in that filing are last-confirmed2024 appointments rather than an asserted complete2026 roster. Its March2024 own employee interview identifies VR software engineer Bhavya Mandali. The current home page publishes no complete named staff directory. An older own biography page includes unfinished placeholder text and partial names; these are excluded from a current staff claim. This exact Delaware corporation and vthera.com domain are distinct from virtualtherapeutics.com and other similarly named therapeutics businesses. Healthcare and technology partnerships do not establish investment participation. No private fund, funding total or acquisition-funded cash allocation is inferred.

Gosia Machniewska is an associate design director at Click Therapeutics. Her company-published employee feature describes designing the cognitive-restructuring experience within a digital therapeutic, with the goal of making difficult treatment activities easier for patients to engage with.

Ioana Medrea, MD, is a scientific advisor to Click Therapeutics and a headache specialist. The University of Toronto states that she joined its Centre for Headache in September 2024 from SUNY Upstate; the Click advisory page’s SUNY affiliation is therefore historical.

Jihan Grant, MD, is a scientific advisor to Click Therapeutics and a headache specialist at Mount Sinai. Her institutional biography describes neurology, headache medicine and interventional pain training and leadership of its headache-treatment and translational-research center.

Merle Diamond, MD, is a headache-medicine specialist and scientific advisor to Click Therapeutics. Her clinical institution now publishes her at Endeavor Health Diamond Headache & Migraine Center; the older Click biography’s independent clinic title is treated as historical.

Patrick Tan is a data scientist at Click Therapeutics. His own company feature describes collaboration with machine-learning, data-engineering, software and clinical-development teams to analyze user behavior and support therapeutic development. He is distinct from the epigenomics researcher and Auristone co-founder of the same name.

Stewart Tepper, MD, FAHS, is a scientific advisor to Click Therapeutics. He is a headache-medicine specialist whose published research and educational work includes migraine, headache therapies and neuromodulation.

Andrea Leonard-Segal, MD, is a scientific advisor to Click Therapeutics. Its biography describes medical practice, regulatory consulting and prior FDA drug-review experience. External career entries are attributed to that source rather than treated as a separately audited current employer directory.

Bruce Leuchter, MD, co-founded Neurvati Neurosciences and GRIN Therapeutics and became Neurvati president, CEO and board member in September2021. A neuropsychiatrist, he trained at New York Presbyterian/Weill Cornell and earlier worked in clinical neuropsychiatry and healthcare finance at Goldman Sachs, Credit Suisse and PJT. He also co-founded Click Therapeutics as its founding neuropsychiatrist, a source-published advisory affiliation distinct from its current executive team. His own Neurvati biography establishes current leadership; older Click external-career entries are historical.

Joseph Kvedar, MD, called Joe Kvedar on Click Therapeutics’ advisory page, works in connected health and dermatology. He advises Click scientifically, and his published academic work examines how digital tools can support healthcare delivery and patient engagement.

Alex Zisson is a healthcare investor whose historical managing-director role at H.I.G. BioHealth Partners is documented in Click’s2021financing announcement. Orbus Therapeutics’ own board biography describes him as a HealthBridge managing director and records earlier healthcare investing at ThomasMcNerney and equity research at HambrechtQuist and its successors. He graduated from Brown University. The current HealthBridge manager directory does not list him, so continuation of that manager position is qualified rather than inferred. His October2026Click director status is sourced and managed separately. The portrait is an authentic named H.I.G. publisher photograph.

Barry Fine, MD, PhD, is a scientific advisor to Click Therapeutics and a physician-scientist at Columbia. His research uses stem cells and engineered heart tissue to study molecular cardiology and potential drug and gene therapies.

Brian Iacoviello, PhD, is a scientific advisor to Click Therapeutics. His work concerns cognitive biases in depression and anxiety and their treatment using cognitive and behavioral approaches. The company’s biography records his psychiatry research affiliation with Mount Sinai.

Bruce Robertson has investment experience at H.I.G. BioHealth and Toucan Capital. Click’s website still lists him as a board member, but its October 1, 2026 SEC filing explicitly says he was elected after the April 7 financing and resigned before that filing. His current H.I.G. HealthBridge title is Senior Advisor; the older Click biography’s managing-director title is historical.

Douglas Langa, called Doug Langa in Click Therapeutics’ directory, serves on its board. His published biography describes senior leadership at Novo Nordisk and earlier pharmaceutical experience. Click’s October 2026 SEC filing states that he was elected after the April 7, 2026 first sale.

Joshua Steinerman, MD, is listed by Click Therapeutics as its founding neuroscientist within the advisory directory. His published career includes neuropsychiatry and clinical development at GW, Jazz and Teva, and academic neurology. This designation does not establish a current full-time employment position.

Nicholas Schork, PhD, advises Click Therapeutics scientifically. His research concerns quantitative medicine, genomics and individual differences in treatment response. Company and XPRIZE biographies record his work at the Translational Genomics Research Institute; he also appears as a historical Click director in early issuer filings.

Rick Rosen is co-president of H.I.G. Capital and shares day-to-day oversight and fund investment-committee responsibilities with Douglas Berman. He joined H.I.G. in1998 after work at General Electric and GECapital. He studied economics at Stanford and earned a Harvard MBA. The HealthBridge affiliation is shared-platform governance.

Industrial software executive with more than 25 years in software, including Microsoft and leadership of Cognite’s partner and alliances business.

Intelecy founder who moved from CEO to focus on product development as CTO when Camilla Gjetvik was appointed in January 2024. Current CTO tenure is not separately reaffirmed by the executive directory.

AI executive and former Boost.ai COO with experience scaling software companies internationally.

Corporate venture investor and startup founder with experience establishing venture units and serving on company boards.

Entrepreneur with startup experience in Silicon Valley and Europe and former CEO of student accelerator Insj UiO.

Serial technology entrepreneur who helped found Kantega and Signicat and previously led technology investing at Investinor.

SaaS revenue executive with previous leadership roles at Uniphore, Boost.ai and Zuora.

Cleantech and industrial investor with earlier roles at SINTEF, the Research Council of Norway and Yara.

Hemispherian is an Oslo-based clinical-stage pharmaceutical company developing investigational small-molecule medicines for aggressive cancers. Its GLIX compounds are designed to activate the TET2 enzyme and trigger cancer-cell DNA damage through an epigenetic mechanism. The lead oral candidate, GLIX1, is being developed with BioLineRx in a Phase 1/2a study for recurrent and progressive glioblastoma and other high-grade gliomas; first patient dosing was announced in April 2026. Its pipeline also includes GLIX5 for platinum-resistant ovarian cancer. These are investigational therapies, and clinical efficacy has not yet been established.

Intelecy develops a no-code industrial AI platform that lets plant engineers and operators build and deploy machine-learning models using production and process data. It connects factory systems to real-time predictions and process optimization tools, helping customers anticipate equipment problems, improve production quality and capacity, and reduce energy use, waste and emissions. Its software serves process industries including chemicals, food and beverages, energy, mining and minerals, and water treatment. The Oslo-based company provides data exploration tools alongside its industrial AI models.

Douglas Berman is co-president of H.I.G. Capital, published as shared executive management on the HealthBridge site. He joined H.I.G. in1996 and previously worked at Bain. His education includes economics at the University of Virginia and an MBA from Wharton. The current capacity is parent-platform oversight rather than a claimed separate GP directorship of every fund.

Pharmaceutical-development specialist and Synthon founding partner with experience in regulatory strategy, manufacturing, quality and commercialization.

Mount Sinai neurosurgeon and professor specializing in brain tumors, image-guided surgery and translational gene and stem-cell research.

Stanford neurosurgery department chair specializing in brain tumors, trigeminal neuralgia and neurological cancer immunotherapy.

Life-sciences investor and company builder with more than 30 years in technology commercialization, business development and M&A.

Anthony Costello is a Click Therapeutics board member and is identified by the company as CEO of Medidata. His earlier career includes Medidata Patient Cloud and Mytrus. Click’s 2025 SEC filing states that he joined the board in connection with that financing.

Brian Schwartz is H.I.G. Capital’s CEO and a member of its executive committee, providing strategic direction across its global investment strategies including HealthBridge. He joined H.I.G. in1994 and previously spent six years as co-president. Earlier roles included PepsiCo strategy and DillonRead investment banking. He holds University of Pennsylvania and Harvard Business School degrees.

Jeffrey Berkowitz is a Click Therapeutics board member. His company biography identifies leadership at Real Endpoints and prior executive experience at UnitedHealth Group and Walgreens. The October 2026 SEC filing confirms his issuer director role.

Tony Tamer is a founder and executive chairman of H.I.G. Capital, named in HealthBridge’s shared parent-management directory. He previously was a Bain partner and works with early-stage and middle-market companies. He studied at Rutgers, Stanford and Harvard Business School. The affiliation does not establish a personal check into every strategy portfolio company.

Sami Mnaymneh is a founder and executive chairman of H.I.G. Capital, published in HealthBridge’s shared executive-management directory. He led the firm as CEO from its1993inception until2026. Previously he was a Blackstone managing director and worked at Morgan Stanley. He studied at Columbia and earned Harvard law and business degrees. This is shared platform governance, not separately asserted employment by every HealthBridge LP.

H.I.G. HealthBridge is the healthcare growth-equity investment strategy previously known as H.I.G. BioHealth Partners, as confirmed by its own rebranding notice and higbio.com redirect. It invests in medical devices, biopharmaceuticals, digital health, tools and diagnostics, and product-related services, supporting commercial strategy, growth, management recruitment and operational development. Its direct portfolio includes prescription digital therapeutics company Click Therapeutics, CNS-focused Arvelle Therapeutics, augmented-reality surgical-navigation company Augmedics and medical-device companies. Click’s ownOctober2021announcement names BioHealth as a USD52M Series B co-lead; the exact subscribing LP is not inferred. The SEC-registered umbrella adviser is H.I.G. Capital, LLC, CRD160711. Its March2026FormADV identifies separate HealthBridge Advisors I/II general partners and HealthBridge Capital Partners I/II Delaware LPs. ExactFormD file numbers reconcile these current fund names with historical BioVenturesII and BioHealthIII, without creating duplicate funds for aliases. The published current team comprises shared parent-platform executive leadership and Bruce Robertson as Senior Advisor. Alex Zisson’s historical BioHealth managing-director role and portfolio-company board descriptions are documented separately; he is absent from the current manager roster, so continued manager employment is not asserted solely from older biographies. This strategy profile is distinct from H.I.G. Growth Partners and the whole H.I.G. Capital organisation. Parent-wide USD75B AUM, 500professionals and aggregate transaction counts are not individual HealthBridge capital or team size.

Maria Forero is an Accelmed senior advisor and serves on Click Therapeutics’ board. Her work spans healthcare operations, investing and business development. She founded and managed Ridgetop Health Fund and previously held leadership roles at Novartis and healthcare investment-banking responsibilities at Morgan Stanley. Her studies include human genetics and public health.

Muzammil Mansuri, PhD, chairs Click Therapeutics’ board. The company’s published biography records venture work at F-Prime Capital and prior executive roles at Sanofi, Gilead and industry biotechnology companies. Those external career entries are source-published history rather than a separately verified current employer roster.

Viveca Livezey, MD, FAAN, is chief medical advisor at Click Therapeutics. She contributes neurological and medical expertise to its development of digital therapeutics; the company publishes her named biography and portrait.

Ritesh Manchanda heads engineering at Click Therapeutics, according to its current company directory. A named authentic portrait is published; further career or educational details are not established by this source.

Daniel Rimm, also called Dan Rimm in the company’s employee feature, heads product at Click Therapeutics. His published account emphasizes collaboration across clinical, technology and science teams in designing software-based treatments.

Cassandra Snipes, PhD, is head of science at Click Therapeutics, according to its current leadership directory. The source publishes an authentic named portrait but no detailed career biography; additional education and prior employers are not assumed.

Sarah Jackson leads business development and alliance management at Click Therapeutics. Her work concerns the company’s pharmaceutical collaborations and commercial partnerships; earlier company announcements also identified her as chief of staff.

Tarique Collins is chief legal officer at Click Therapeutics. A lawyer with privacy and information-management credentials, he oversees the company’s legal function in the development of digital medicines.

Rich DeNunzio, also identified as Richard DeNunzio in company releases, leads commercial strategy at Click Therapeutics as chief commercial officer. The company publishes a named biography and authentic portrait.

Austin Speier is chief strategy officer at Click Therapeutics. His published work includes corporate strategy, scientific development and digital medicine; his current role is confirmed by the company’s own leadership directory.

David Benshoof Klein founded Click Therapeutics in 2012 and is its chief executive officer and a board member. His work spans software-based medical treatments, healthcare entrepreneurship and therapeutic development.

Randall Stanicky is chief financial officer of Click Therapeutics. He previously covered healthcare as an equity analyst at RBC Capital Markets and Goldman Sachs, including research into digital health. His published board experience includes the Children’s Tumor Foundation and TherapeuticsMD.

Click Therapeutics, Inc. develops prescription digital therapeutics using neuroscience, behavioral interventions, patient-centered software design and AI-enabled personalization. Founded in2012, it is headquartered in New York with a Boston office. Its products include the Otsuka collaboration Rejoyn for adjunctive major-depressive-disorder treatment, CT-132 for episodic migraine, acquired AspyreRx technology, and Boehringer Ingelheim collaboration Motivista (CT-155). FDA510(k) K254038 records Motivista clearance on July30,2026; the company announced it October5. Its indication is adjunctive treatment of negative schizophrenia symptoms in clinically stable adults under clinician care, not a general authorization of every pipeline program. Other programs remain at distinct development stages. Click SE extends its software platform to drug-related software and software-enhanced therapies. Published executives, board members and scientific advisers are represented separately; the October2026 SEC filing overrides a stale directory entry for resigned director Bruce Robertson. Financing records distinguish equity, notes, converted debt, loan proceeds, facility capacity and commercial collaboration funding. Better Therapeutics assets were acquired in2024; that asset purchase does not imply a legal merger or a disclosed acquisition price.

Link Medical develops precision temperature-management devices and consumables for neurocritical and other intensive-care applications. Its products include intravascular and non-invasive surface temperature-control systems, with research focused on neuroprotection after stroke or traumatic brain injury and temperature management for cardiac arrest, surgery and organ transplantation. The Hangzhou company also develops adaptive temperature-control software and investigates AI-assisted personalized temperature profiles.

Mindtrix develops implantable brain-computer interfaces for artificial vision and movement control. Its visual-reconstruction system combines external image capture and processing with flexible electrodes that electrically stimulate the visual cortex, aiming to restore useful visual perception for people with severe vision loss. The company develops closed-loop neural stimulation, brain-machine co-learning algorithms and implantable-interface hardware, and also researches spinal-cord stimulation and intraoperative cortical mapping. Its visual-reconstruction technology is undergoing clinical research and engineering development.

Neuroscientist and co-founder of Mindtrix. Conducted implantable brain-computer interface research at the University of California, Berkeley and Duke University before returning to the Chinese Academy of Sciences Institute of Automation in 2023.

Neuroscientist and co-founder of Mindtrix. Studied primate visual-system structure and function and neural encoding and decoding at the Salk Institute before founding the company with Liu Bing in 2024.

Cédric Mirri is published by Sofilaro Calen as Analyst / Middle Office. The current public directory identifies this role but does not supply a longer career biography.

Marine Larnaudie is published by Sofilaro Calen as Apprentice Analyst / Middle Office. The current public directory identifies this role but does not supply a longer career biography.

Solenn Marcel is published by Sofilaro Calen as Analyst / Middle Office. The current public directory identifies this role but does not supply a longer career biography.

Julie Streiff is published by Sofilaro Calen as Analyst / Middle Office. The current public directory identifies this role but does not supply a longer career biography.

Industrial47 is an Indian venture investor backing pre-seed companies developing frontier technologies for national security, space and energy. Its strategy supports hardware and engineering businesses building capabilities such as satellite systems, advanced materials, cybersecurity and nuclear fusion. It publishes initial cheque sizes of USD500,000 to USD1.5 million and operates from Bengaluru. Founder Rahul Seth is the solo general partner and the manager publishes an advisory group with space, product and defence intelligence experience. The website’s USD250 million figure describes follow-on capital raised by companies, rather than the manager’s fund size.

Published as Lt. Gen. AK Bhalla, former Director General of the Defence Intelligence Agency. The manager publishes initials rather than an expanded given name.

Matthieu Rudi is published by Sofilaro Calen as Administrative and Finance Director. The current public directory identifies this role but does not supply a longer career biography.

Solo general partner investing in Indian frontier technology. Former scouting director at Antler India, entrepreneur and Indian Army Reserves major; alumnus of BITS Pilani and the Indian Military Academy.

Published Industrial47 advisor whose current external role is product at Nvidia.

Lucie Ayala is published by Sofilaro Calen as Investment Director, Innovation. The current public directory identifies this role but does not supply a longer career biography.

Lucas Grillard is published by Sofilaro Calen as Investment Director, Innovation. The current public directory identifies this role but does not supply a longer career biography.

Constance Arnal is published by Sofilaro Calen as Fund Director, Renewable Energy. The current public directory identifies this role but does not supply a longer career biography.

Alison Campbell is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. Her technology-transfer career includes KnowledgeTransferIreland, the MedicalResearchCouncil and King’sCollegeLondon. She became the GovernmentOfficeforTechnologyTransfer chief executive in2022. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Betty Bonnardel is published as UKI2S Space Advisor and Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. She founded AB5Consulting and FarmerCharlie, combining space and satellite expertise with engineering, energy and agricultural technology. Her training includes aeronautical/space engineering and an MBA. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Colin Story is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His career includes GEHealthcare, Oxford technology transfer, OrganOx and co-founding OxSonics, followed by therapeutic-company board and executive work. The fund records his advisory appointment inNovember2023. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Eddie Alleyn is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. He previously led HMGCC during2011–2016 following government work in defence, security and foreign affairs, and now advises technology ventures; he is an IET Fellow. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

Fabien Mansalier is published by Sofilaro Calen as Fund Director, Renewable Energy. The current public directory identifies this role but does not supply a longer career biography.

Jerome S. Engel is published as Investment Governance Board Member with Future Planet Capital. His work centres on innovation, entrepreneurship and venture capital through teaching and advisory work for business and government. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.

John Tingay is published as UKI2S Advisory Board Member within the UK Innovation & Science Seed Fund ecosystem. His engineering experience spans semiconductor and electronics equipment, wafer-level packaging, imaging and particle-accelerator systems, including bringing new technologies into commercial production. This affiliation retains the published investment, operating or external-advisory scope; it does not establish a personal cash check or an appointment to every group subsidiary.